Medical devices, healthcare technology and the business of care
PMA approval · P210007

Vivistim System

Mobia Medical, Inc. · Decision date Aug 27, 2021

FDA DECISIONP210007

What did the FDA approve?

FDA records P210007 as an original PMA application. The recorded decision is approval, dated Aug 27, 2021.

FDA approval order statement

Approval the MicroTransponder Vivistim Paired VNS System (Vivistim System) is intended to be used to stimulate the vagus nerve during rehabilitation therapy in order to reduce upper extremity motor deficits and improve motor function in chronic ischemic stroke patients with moderate to severe arm impairment.
Regulatory pathway
Original PMA
Clinical specialty
Physical Medicine
Decision date
Aug 27, 2021

FDA source record

Regulatory record facts

Identifier
P210007
Regulatory pathway
Premarket approval application
Product code
QPY
Decision code
APPR
Decision date
Aug 27, 2021
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, autonomic nerve, implanted for stroke rehabilitation.

Product code
QPY
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P210007 received

    Application receipt date recorded by FDA.

  2. P210007 · FDA decision

    APPR

  3. P210007/S008 · Related supplement

    Vivistim Paired VNS System

  4. P210007/S012 · Related supplement

    Vivistim Paired VNS System

  5. P210007/S014 · Related supplement

    Vivistim Pair VNS System

Timeline entries are records held by MedtechLedger for P210007. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P210007

Product / regulatory recordCompanyPathwayDecision dateSource
Vivistim SystemP210007/S007
Mobia Medical, Inc.PMA supplementSep 3, 2025FDA
Vivistim SystemP210007/S010
Mobia Medical, Inc.PMA supplementJan 28, 2026FDA
Mobia Medical, Inc.PMA supplementFeb 26, 2026FDA
Vivistim SystemP210007/S011
Mobia Medical, Inc.PMA supplementMar 2, 2026FDA
Mobia Medical, Inc.PMA supplementApr 1, 2026FDA
Vivistim SystemP210007/S013
Mobia Medical, Inc.PMA supplementApr 10, 2026FDA
Mobia Medical, Inc.PMA supplementJun 18, 2026FDA
Vivistim SystemP210007/S015
Mobia Medical, Inc.PMA supplementSep 16, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Mobia Medical, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2802 Flintrock Trace, Suite 226, Austin, TX, 78738

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records